IVERIC bio

IVERIC bio ROA

Delisted

The Return on Assets (ROA) of IVERIC bio (ISEE) as of Oct 22, 2026 is -26.36 %. In the previous year, Return on Assets (ROA) was -29.34 % — a change of -10.17% (higher).

ROA

-26.36 %

YoY

-10.17%

Last updated:

In 2022, IVERIC bio's return on assets (ROA) was -26.36 %, a -10.17% increase from the -29.34 % ROA in the previous year.

The IVERIC bio ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-24.65 USD
Jan 1, 2016
-64.55 USD
Jan 1, 2017
65.05 USD
Jan 1, 2018
45.99 USD
Jan 1, 2019
-45.21 USD
Jan 1, 2020
-39.01 USD
Jan 1, 2021
-29.34 USD
Jan 1, 2022
-26.36 USD
The IVERIC bio ROA history
YEARROAYoY
-26.36 %-10.17%
-29.34 %-24.78%
-39.01 %-13.72%
-45.21 %-198.30%
45.99 %-29.29%
65.05 %-200.76%
-64.55 %+161.87%
-24.65 %+25.12%
-19.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

ROA Details

Understanding IVERIC bio's Return on Assets (ROA)

IVERIC bio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing IVERIC bio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider IVERIC bio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in IVERIC bio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about IVERIC bio stock

Return on Assets (ROA) of IVERIC bio is -26.36 % in 2022.

Return on Assets (ROA) of IVERIC bio changed from -29.34 % to -26.36 %, representing a -10.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s IVERIC bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IVERIC bio

All Key Metrics — IVERIC bio